Chronic but not acute intracerebroventricular administration of amyloid β‐peptide(25–35) decreases somatostatin content, adenylate cyclase activity, somatostatin‐induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus | Publicación